Health ❯ Healthcare ❯ Cancer Treatment

Targeted Therapy

EGFR Inhibitors Antibody Drug Conjugates Daraxonrasib Menin Inhibitors Drug Approval HER2-directed Therapy Small Molecule Compounds Smart Cancer Drug XPO1 Protein NSD2 Inhibition

3 ARTICLES

2w ago

Amivantamab Plus Chemotherapy Shows Longest Survival for EGFR Exon 20 Insertion Lung Cancer

A prespecified statistical adjustment for on‑protocol crossover produced a significant survival advantage, a result that could shape first‑line treatment choices.

3 ARTICLES

last mo.

Enhertu Improves Progression‑Free Survival in Phase 3 HER2‑Mutant Lung Cancer Trial

5 ARTICLES

2mo ago

AstraZeneca Licenses Global Rights to Zegfrovy From Dizal

3 ARTICLES

3mo ago

Engineered CAR T Cells Targeting MUC16 Control Bladder Tumors in Mice

3 ARTICLES

4mo ago

Selpercatinib Dramatically Cuts Recurrence in Early-Stage RET-Positive Lung Cancer

4 ARTICLES

4mo ago

Waterloo Scientists Ready Engineered Tumor‑Eating Bacteria for Preclinical Testing

3 ARTICLES

8mo ago

Study Finds Blood Test Predicts Tarlatamab Benefit in Small Cell Lung Cancer

3 ARTICLES

8mo ago

Japan's 54,000-Patient Cancer Panel Study Finds Many Targets, Few Treatments

7 ARTICLES

9mo ago

Tucatinib Added to First-Line HER2 Maintenance Prolongs Progression-Free Survival in Phase 3 Trial

11 ARTICLES

9mo ago

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

5 ARTICLES

9mo ago

KOMET-007 Shows 600 mg Ziftomenib Plus Venetoclax/Azacitidine Achieves Deep Remissions in NPM1‑Mutated AML

8 ARTICLES

9mo ago

Shorter, Chemo-Free Strategies Match or Beat Standard Care in Adult Leukemias at ASH

3 ARTICLES

11mo ago

Enhertu Delivers Pivotal Gains in Early HER2-Positive Breast Cancer

3 ARTICLES

11mo ago

Final FLAURA2 Data Show Osimertinib Plus Chemotherapy Extends Survival in EGFR-Mutant Lung Cancer

6 ARTICLES

11mo ago

Niraparib Add-On Slows Progression in Advanced Prostate Cancer, Phase III Trial Shows

6 ARTICLES

this yr.

Engineered CAR-T Cells Target PD-L1 to Deliver IL-12 at Tumors, Showing Solid-Tumor Gains in Mice

3 ARTICLES

last yr.

Glycan-Targeting ‘GlyTR’ Therapy Kills Diverse Cancers in Preclinical Tests

Targeted Therapy

Amivantamab Plus Chemotherapy Shows Longest Survival for EGFR Exon 20 Insertion Lung Cancer

Enhertu Improves Progression‑Free Survival in Phase 3 HER2‑Mutant Lung Cancer Trial

AstraZeneca Licenses Global Rights to Zegfrovy From Dizal

Engineered CAR T Cells Targeting MUC16 Control Bladder Tumors in Mice

Selpercatinib Dramatically Cuts Recurrence in Early-Stage RET-Positive Lung Cancer

FDA Extends Review of AstraZeneca’s Camizestrant

Zoldonrasib Shows Promising Early Efficacy in KRAS G12D Lung Cancer

CD70-Targeted HIT Cells Eradicate Solid Tumors in Mice

Waterloo Scientists Ready Engineered Tumor‑Eating Bacteria for Preclinical Testing

Study Finds Blood Test Predicts Tarlatamab Benefit in Small Cell Lung Cancer

Never miss stories about

Targeted Therapy

Japan's 54,000-Patient Cancer Panel Study Finds Many Targets, Few Treatments

Tucatinib Added to First-Line HER2 Maintenance Prolongs Progression-Free Survival in Phase 3 Trial

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

KOMET-007 Shows 600 mg Ziftomenib Plus Venetoclax/Azacitidine Achieves Deep Remissions in NPM1‑Mutated AML

Shorter, Chemo-Free Strategies Match or Beat Standard Care in Adult Leukemias at ASH

Enhertu Delivers Pivotal Gains in Early HER2-Positive Breast Cancer

Final FLAURA2 Data Show Osimertinib Plus Chemotherapy Extends Survival in EGFR-Mutant Lung Cancer

Niraparib Add-On Slows Progression in Advanced Prostate Cancer, Phase III Trial Shows

Engineered CAR-T Cells Target PD-L1 to Deliver IL-12 at Tumors, Showing Solid-Tumor Gains in Mice

Glycan-Targeting ‘GlyTR’ Therapy Kills Diverse Cancers in Preclinical Tests

Never miss stories about

Targeted Therapy